Chester County News and Community Website
WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has announced its financial results for the third quarter ending September 30, 2024, alongside significant business updates. The company achieved progress in …
Windtree Therapeutics Reports Q3 Results and Highlights Key Business Achievements Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has announced a significant leadership change as Craig Fraser steps down from his role as Chief Executive Officer, effective December 1, 2024. …
Leadership Transition at Windtree Therapeutics: Fraser Retires, Latkin Takes Helm Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has announced the issuance of a new patent for istaroxime in Hong Kong, titled “Istaroxime-containing intravenous formulation for the treatment of heart …
Windtree Therapeutics Secures Hong Kong Patent for Istaroxime in Heart Failure Treatment Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has initiated patient enrollment for its SEISMiC C trial, targeting SCAI Stage C cardiogenic shock. This trial marks a pivotal step in …
Windtree Therapeutics Begins SEISMiC C Trial for Advanced Cardiogenic Shock Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has announced the completion of national phase filings for its istaroxime patent applications across key global markets, including the United States, Germany, …
Windtree Therapeutics Secures Global Patent Filings for Istaroxime Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has announced a significant advancement in its cardiovascular portfolio with the issuance of a new patent for its drug istaroxime in Japan. The …
Windtree Therapeutics Secures Patent for Heart Failure Treatment in Japan Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has announced the publication of its SEISMiC Phase 2b trial design by the European Society of Cardiology Heart Failure. The trial is exploring …
Windtree Therapeutics Publishes SEISMiC Phase 2b Trial Design for Cardiac Treatment Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has announced encouraging topline results from its Phase 2b SEISMiC Extension Study investigating istaroxime in patients experiencing early cardiogenic shock due to heart …
Windtree Therapeutics Announces Positive Results in Heart Failure Study Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) is set to host a virtual Investor Day Presentation on October 1 at 3 pm ET, where it will unveil promising new results …
Windtree Therapeutics Announces Key Investor Day for Groundbreaking Heart Treatment Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has reported promising outcomes from its Phase 2b SEISMiC Extension Study, showcasing the potential of istaroxime in managing early cardiogenic shock caused by …
Windtree Therapeutics Announces Promising Results for Heart Failure Drug Read More